TP53 and colorectal carcinoma: These findings provide novel insights pertaining the mechanism by which mutant p53 enhances CRC development, which involves the expansion of CSCs sub-populations within CRC tumors, and underscore the importance of targeting these sub-populationss for CRC therapy.